Abstract
Gliomas, particularly high-grade gliomas like glioblastomas, represent some of the most formidable challenges in oncology. These brain tumors are notorious for their resistance to conventional therapies, including surgery, chemotherapy, and radiation. The recent systematic review and meta-analysis protocol offers a promising direction by focusing on Tumor Mutation Burden (TMB) and Tumor Microenvironment (TME) as potential biomarkers for treatment outcomes and prognosis in gliomas.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Biomedical Research & Environmental Sciences
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
